Fred Hutch and UW researchers secure Breast Cancer Research Foundation funding

Annual, renewable awards will support research in breast cancer vaccine development, risk assessment and treatment response
four researchers' profile photos
From left to right, Fred Hutch and UW researchers Drs. Heather Parsons, Christopher Li, Mary L. (Nora) Disis and Mary-Claire King have recently been awarded grants by the Breast Cancer Research Foundation. Fred Hutch and UW file photos

Breast cancer experts from Fred Hutch Cancer Center and the University of Washington have been awarded grants by the Breast Cancer Research Foundation (BCRF). They will use their awards to fund research into several critical areas of breast cancer research, including perfecting a vaccine targeting breast cancer risk factors in people with obesity, identifying molecular signatures in primary tumors that can predict severity and recurrence risks, and examining tumor DNA in circulating blood to determine how well a treatment plan is working.

The honorees are Heather Parsons, MD, MPH, program head for Fred Hutch’s Breast Oncology Program; Christopher Li, MD, MPH, senior vice president and director of the Public Health Sciences Division; Mary L. (Nora) Disis, MD, professor in the Clinical Research Division and director of the Cancer Vaccine Institute at UW; and Mary-Claire King, PhD, American Cancer Society professor of Medicine and Genome Sciences at UW and an affiliate member of Fred Hutch. Collectively, these researchers have been awarded over $900,000 this year in grants that can be renewed by invitation from the BCRF.

Founded by Evelyn H. Lauder in 1993, the BCRF supports investigators focusing on all aspects of breast cancer research, from prevention and risk prediction to diagnosis, treatment, and survivorship. The 2026-2027 grant cycle provides over $75 million in scientific grants to support over 280 researchers in 18 countries around the globe.

Parsons, a medical oncologist and holder of the Maudslien Endowed Chair in Breast Cancer Precision Oncology Research, will use her new BCRF award to support research helping to develop blood-based DNA tests to capture circulating tumor DNA (ctDNA) and analyze how well the tumor is responding to treatment. 

Current ctDNA tests can detect tiny fragments of tumor DNA that have separated from the primary tumor and entered the bloodstream. Parsons’ research focuses on understanding how this DNA can be analyzed to help optimize treatment. ctDNA can offer insight into how a patient is responding to treatment, as its levels in the bloodstream can rise or fall rapidly depending on how the underlying tumor is responding to therapy.

But, Parsons cautioned, there is still much that researchers don’t understand about ctDNA.

“When should we draw ctDNA from a patient?” she said. “Can we do it with smaller amounts of blood, in a way that’s less intrusive for a patient? Can patients do it at home themselves?”

For her BCRF-funded project, Parsons and her collaborators will follow newly-diagnosed breast cancer patients from the onset of therapy over regular intervals to analyze ctDNA found in small blood samples. These samples will be collected in small amounts, such as via a small blot from a finger prick, similar to how people with diabetes test blood sugar levels. They will compare these samples to other clinical test results to understand how ctDNA reflects the activity of the primary tumor during treatment. 

Parsons aims to determine where ctDNA testing may be most useful in assessing treatment efficacy for breast cancer patients. Her research could lead to the establishment of clinical standards for how and when to analyze ctDNA.

In an earlier study published in March in the Journal of Clinical Oncology, Parsons and her collaborators showed that the presence or absence of ctDNA after treatment for the high-risk subtypes HER2-positive and triple negative breast cancer was strongly correlated with whether a patient was at exceptionally high risk for cancer recurrence. The current study builds on these findings by studying patients from the beginning of their treatment, tracking them over time and testing ctDNA levels at multiple very specific intervals to learn what happens in the hours, days and weeks after beginning treatment. 

“This will help us to get an accurate estimate of how frequently the ctDNA test will be positive [in different subtypes of breast cancer], both at the beginning and over time, and what features are related to how often those tests are positive or negative, both with respect to the patients themselves, and to the cancer,” Parsons said.

After graduating from college, Parsons worked in a lab headed by Titia De Lange, PhD, at Rockefeller University in New York City before beginning her medical training. She was pleased to see De Lange in attendance at the mid-October BCRF event in New York City celebrating this year’s grant recipients.

“It was very cool to see her, among many others in the group whom I admire and who have mentored me,” Parsons said. “I’m very grateful to BCRF. It’s a really wonderful organization and I am excited to be supported by them and to now be part of that community."

Article continues below.

 Be the first to hear what's next

Learn about Fred Hutch’s groundbreaking discoveries and patient care innovations in our free monthly newsletter.

Identifying molecular signatures that predict breast cancer recurrence

An epidemiologist and holder of the Helen G. Edson Endowed Chair for Breast Cancer Research, Li will use his BCRF award for a project identifying genetic features of breast cancer tumors that are closely associated with cancer recurrence. 

“One of the concerns that many breast cancer survivors have is whether their cancer is going to come back,” Li said. “And so we’re really interested in whether we can identify patients at particularly high risk of a recurrence who may warrant more frequent follow-up screening or different types of treatments, versus those whose likelihood of recurrence is low.”

Li and his team will examine the genetic characteristics of primary breast cancer tumors as well as normal cells taken from patient saliva called buccal cells that represents the “germline” DNA, the genetic information that a patient inherited from their parents that does not contain cancer. Through a process known as whole-genome sequencing, a technology that has become an efficient and affordable way to generate and analyze DNA sequences, the entire genome of these cells can be mapped and analyzed. Li plans to compare the germline DNA to the cancer cell DNA to identify features of the cancer genome that could correlate with specific subtypes and with recurrence risk. 

“The genome of the cancer is completely different from that germline DNA,” Li explained, “and what we’re interested in is looking at the differences. What are the ways that a person’s genome has mutated in the form of this cancer? What may be driving its development, as well as future potential metastasis?” 

The study will examine a cohort of 3,904 patients with different cancer subtypes and different disease prognoses who have been followed for up to 15 years or more after a primary breast cancer diagnosis. Patients were recruited both from the Seattle area and from the Albuquerque, New Mexico metropolitan area, with a focus on identifying patients with triple-negative breast cancer, a subtype that is generally more aggressive and difficult to treat. The cohort contains approximately 1,400 triple negative patients, about 600 patients with HER2-receptor positive breast cancer, and about 2,000 patients with more common estrogen or progesterone-receptor positive subtypes.

This is Li’s fifth year as a recipient of a one-year, renewable $225,000 BCRF award. In prior funding cycles, Li used a spatial proteomics platform that could map individual cells to study how “neighborhoods” of cells situated near breast cancer cells act and potentially protect tumor cells from the body’s immune system. Li said that he appreciates the BCRF’s commitment to high-risk, high-reward breast cancer research looking at novel ways of understanding tumor genetics and behavior.

“The funding mechanism provides a lot of freedom to be able to pursue different types of projects that can be higher risk than what we might be able to get funded through other, more traditional channels. So it’s provided a lot of freedom in that regard,” he said.

Li’s hope is that his research will lead to screening protocols for breast cancer patients when they are first diagnosed that could potentially identify tumor markers associated with higher risks of early relapse. By identifying higher-risk patients at the outset of diagnosis, a personalized treatment and follow-up plan could be created to help reduce their long-term cancer risks.

“Then we can try to design potential interventions based on what we’re finding,” Li said.

Article continues below.

More on Breast Cancer From Fred Hutch

Learn more about our targeted approach to the diagnosis and treatment of breast cancer.

Breast Cancer Screening and Diagnosis

Regular screenings can help detect breast cancer early, when it’s easier to treat. Learn more about how breast cancer is diagnosed.

Breast Cancer Facts and Resources

If you need general information about breast cancer, we have compiled foundational facts, information and resources to help you learn about the disease.

Breast Cancer Specialists

Meet your breast cancer care team at Fred Hutch, from medical oncologists to supportive care specialists, all dedicated to your treatment.

Breast Cancer Research and Clinical Trials

Dig deeper into the ongoing research and clinical trials for breast cancer at Fred Hutch, and read about the latest news and developments.

Perfecting a vaccine targeting obesity-related breast cancer risks

Disis, a UW physician-researcher, will use her BCRF award to fund a project to test and improve the efficacy of a vaccine that has been shown to reduce the risk of breast cancers that develop due to fat inflammation in breast tissue.

Obesity was first identified as a specific risk factor for breast cancer in 1976, when an early study showed that patients with obesity (defined as more than 20% over their standard body weight) had worse breast cancer outcomes and larger primary tumors when compared to patients at normal weight. Subsequent studies have identified additional insights into breast cancer and obesity, such as a 2007 study reporting that weight gain throughout adulthood was associated with increased hormone-positive breast cancer risk in post-menopausal patients who did not use hormone replacement therapy. 

Scientists now understand that inflammation caused by some immune system cells that enter fat tissue create imbalances in cellular metabolism that can lead to cancer.

Disis’ lab created a vaccine to address the inflammation in fat tissue before a cancerous state can take hold in the cell. The Adipocyte-Directed Vaccination (ADVac) was designed to target specific proteins found at abnormally high levels in obese as compared to normal weight fat. The vaccine affects immune system cells known as T cells. T cells exposed to ADVac secrete anti-inflammatory messenger proteins known as Type 2 cytokines that can travel to obese fat tissue. These proteins help reduce inflammation in the fat tissue and also help increase T-regulatory cells, a subset of T cells which act as “brakes” on the immune system, further reducing inflammation.

In a preclinical breast cancer model, ADVac corrected metabolic dysfunction in obese fat cells and infiltrating T cells, significantly delaying tumor onset and slowed tumor growth.

In the current study, Disis will explore different formations of the vaccine to determine how to optimize its effectiveness. She will evaluate ADVac’s safety in preclinical models. The study will also investigate whether the vaccine can reduce breast cancer development in preclinical models without obesity but with fatty liver disease (also known as metabolic dysfunction-associated steatotic liver disease, or MASLD), which is characterized by an excess of fat in the liver of people who drink alcohol rarely, or not at all and is highest in populations with metabolic syndrome.

“Fatty liver disease is very common and can lead to liver damage and increased breast cancer risk in both obese and non-obese individuals,” Disis wrote in her research proposal. 

Disis will test the efficacy of ADVac in non-obese preclinical models with MASLD to observe whether the vaccine improves both the liver disease and cancer outcomes. The ultimate goal is a clinical trial approved by the U.S. Food and Drug Administration that could lead to the use of ADVac in patients for breast cancer and fatty liver disease prevention.

Unraveling breast cancer’s hidden genetic clues

King is known for her studies over 50 years in breast cancer genetics. She discovered BRCA1, one of the ultimately-defined 10 genes responsible for inherited predisposition to breast cancer. 

Since 1997 she has received funding from the BCRF for projects including the development of the BROCA Cancer Risk Panel, the first-ever gene sequencing panel for any disease, and the use of long-read DNA and RNA sequencing to detect changes in the genome, including in the non-coding regions, that could be missed by sequencing techniques that look only at shorter portions of the genome directly involved in protein coding.

“The goal of my research has been to identify and characterize the genes and mutations responsible for inherited breast cancer, working directly with affected families and using tools from genetics, genomics, statistics, and molecular and cell biology,” King wrote in her 2027 BCRF research application. “For women to learn if they are at genetically high risk of breast cancer, it is critical to be able to identify all types of breast-cancer-causing mutations with complete accuracy and at low cost.”

Her current BCRF-funded project focuses on studying genetic causes of breast cancer in families where there is no obvious underlying genetic mutation identified by current genetic testing methods. King aims to use long-read DNA and RNA sequencing to examine genomic regions that could predispose a patient to breast cancer that cannot be found using other sequencing techniques. Concurrently, she plans a pilot project to identify inherited genetic variations in regulation of the estrogen receptor gene that could affect the age at which BRCA1 or BRCA2 mutation carriers develop breast cancer, as well as the relative severity of the disease. This project follows publication of the first results of the estrogen receptor story, also supported by the BCRF, in Proceedings of the National Academy of Sciences this year.

“The rationale for both these projects is to discover all possible mechanisms of inherited risk of breast cancer, and to enable women to obtain information about their genetic risk so they can take steps to prevent the disease,” King wrote.

 

These studies are supported by grants BCRF-26-239, BCRF-26-193, BCRF 26-038 and BCRF-26-088 from the Breast Cancer Research Foundation.

read-more

Read more about Fred Hutch achievements and accolades.

nicole-g-boeck

Nicole G. Boeck (née Nazzaro) is a science writer based in Edmonds, WA. Her writing has appeared in Nature, Immunology and Cell Biology, Sky & Telescope, the New York Times and many other publications. She has a BA from Harvard University, an MJ in journalism from the University of California-Berkeley and a postbaccalaureate BS in biochemistry from the University of Washington. Nicole is a member of the National Association of Science Writers. Reach her at nicole@impactmedianw.com or @mnicolen.bsky.social.

Related News

All news
Dr. Christopher Li shares vision for Public Health Sciences Division ‘We don’t want our work to just sit in academic journals, but to impact community’ October 23, 2026
Lobular community celebrates 10 years of progress, vows to ‘keep pedaling’ Patient advocates, clinicians and researchers gather for 2026 ILC Symposium; Fred Hutch joins LARC, new lobular research consortium October 15, 2026
When both cancer and courage run in the family Two Seattle sisters, both diagnosed with BRCA2-driven breast cancer, speak out on importance of genetic testing for hereditary cancers September 28, 2026

Help Us Eliminate Cancer

Every dollar counts. Please support lifesaving research today.